Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii

References

• Douzandeh-MobarrezB, AlizadeH, KafilHS, KarmostajiA. Antimicrobial categories in describing multidrug resistance, extensive drug resistance and pan-drug resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: a systematic review. Rev Med Microbiol. 2021;32:6–11.
   Web of Science ®Google Scholar
• AslamA, GajdácsM, ZinCS, BintiARN, AhmedSI, JamshedSQ. Public awareness and practices towards self-medication with antibiotics among the Malaysian Population. A development of questionnaire and pilot-testing. Antibiotics. 2020;9:97.
   Web of Science ®Google Scholar
• GajdácsM, UrbánE. Epidemiological trends and resistance associated with Stenotrophomonas maltophilia bacteremia: a 10-year Retrospective Cohort Study in a tertiary-care hospital in Hungary. Diseases. 2019;7:41.
   Web of Science ®Google Scholar
• ShlaesDM, BradfordPA. Antibiotics-from there to where?: how the antibiotic miracle is threatened by resistance and a broken market and what we can do about it. Pathog Immun. 2018;3(1):19–43. doi:10.20411/pai.v3i1.23130993248
   PubMedGoogle Scholar
• PfallerMA, FlammRK, DuncanLR, MendesRE, JonesRN, SaderHS. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 gram-negative organisms from Europe and the Asia-Pacific region (2013–2014). Diagn Microbiol Infect Dis. 2017;88(2):177–183. doi:10.1016/j.diagmicrobio.2017.02.02028341098
   PubMed Web of Science ®Google Scholar
• GajdácsM. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24:892. doi:10.3390/molecules24050892
   PubMed Web of Science ®Google Scholar
• WilliamsJD. Beta-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis. 1997;24:494–497. doi:10.1093/clinids/24.3.4949114205
   PubMed Web of Science ®Google Scholar
• HigginsPG, WisplinghoffH, StefanikD, SeifertH. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother. 2004;48(5):1586–1592. doi:10.1128/AAC.48.5.1586-1592.200415105109
   PubMed Web of Science ®Google Scholar
• JiJ, DuX, ChenY, FuY, WangH, YuY. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents. 2013;41(4):400–401. doi:10.1016/j.ijantimicag.2012.12.01423410789
   PubMed Web of Science ®Google Scholar
• ChoiJY, ParkYS, ChoCH, et al. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect. 2004;10(12):1098–1101. doi:10.1111/j.1469-0691.2004.00987.x15606639
   PubMed Web of Science ®Google Scholar
• LeeNY, WangCL, ChuangYC, et al. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy. 2007;27(11):1506–1511. doi:10.1592/phco.27.11.150617963460
   PubMed Web of Science ®Google Scholar
• LaiCC, ChenCC, LuYC, LinTP, ChuangYC, TangHJ. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms. Infect Drug Resist. 2018;11:1441–1445. doi:10.2147/IDR.S17525730237728
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. CLSI supplement M100.
   Google Scholar
• DallenneC, DaCA, DecreD, FavierC, ArletG. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65(3):490–495. doi:10.1093/jac/dkp49820071363
   PubMed Web of Science ®Google Scholar
• GajdácsM, BuriánK, TerhesG. Resistance levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics. 2019;8:143.
   Web of Science ®Google Scholar
• LaiCC, ChenCC, LuYC, ChuangYC, TangHJ. In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Infect Drug Resist. 2019;12:25–29. doi:10.2147/IDR.S18120130588045
   PubMed Web of Science ®Google Scholar
• WangFD, LinML, LeeWS, LiuCY. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against gram-negative bacteria. Int J Antimicrob Agents. 2004;23(6):590–595. doi:10.1016/j.ijantimicag.2003.10.00815194130
   PubMed Web of Science ®Google Scholar
• XuS, LiY, XuX, et al. A case-control study: clinical characteristics of nosocomial bloodstream infections versus non-bloodstream infections of Acinetobacter spp. Clin Infect Dis. 2018;67(suppl_2):S189–S195. doi:10.1093/cid/ciy67130423050
   PubMed Web of Science ®Google Scholar
• LiY, GuoQ, WangP, et al. Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 β-lactamase at a teaching hospital in Shanghai, China. J Microbiol Immunol Infect. 2015;48(1):101–108. doi:10.1016/j.jmii.2014.04.00524863499
   PubMedGoogle Scholar
• NiuT, LuoQ, LiY, ZhouY, YuW, XiaoY. Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control. 2019;8:52. doi:10.1186/s13756-019-0502-x30886705
   PubMed Web of Science ®Google Scholar
• KengklaK, KongpakwattanaK, SaokaewS, ApisarnthanarakA, ChaiyakunaprukN. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22–32. doi:10.1093/jac/dkx36829069421
   PubMed Web of Science ®Google Scholar
• BetrosianAP, FrantzeskakiF, XanthakiA, DouzinasEE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432–436. doi:10.1016/j.jinf.2008.04.00218501431
   PubMed Web of Science ®Google Scholar
• PenwellWF, ShapiroAB, GiacobbeRA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1680–1689. doi:10.1128/AAC.04808-1425561334
   PubMed Web of Science ®Google Scholar
• KazmierczakA, PechinotA, SieborE, CordinX, LabiaR. Sulbactam: secondary mechanisms of action. Diagn Microbiol Infect Dis. 1989;12(4 Suppl):139S–146S. doi:10.1016/0732-8893(89)90126-02591173
   PubMed Web of Science ®Google Scholar
• KrizovaL, PoirelL, NordmannP, NemecA. TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J Antimicrob Chemother. 2013;68(12):2786–2791. doi:10.1093/jac/dkt27523838947
   PubMed Web of Science ®Google Scholar
• YangY, XuQ, LiT, et al. OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2019;63(1). doi:10.1128/AAC.01676-18
   Web of Science ®Google Scholar
• KuoSC, LeeYT, YangLT, et al. Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front Microbiol. 2015;6:231. doi:10.3389/fmicb.2015.0023126284030
   PubMed Web of Science ®Google Scholar
• Durand-RevilleTF, GulerS, Comita-PrevoirJ, et al. ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104. doi:10.1038/nmicrobiol.2017.10428665414
   PubMed Web of Science ®Google Scholar
• MoyaB, BarceloIM, BhagwatS, et al. Potent beta-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01238-17
   Web of Science ®Google Scholar
• Papp-WallaceKM, SenkforB, GattaJ, et al. Early insights into the interactions of different beta-lactam antibiotics and beta-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrob Agents Chemother. 2012;56(11):5687–5692. doi:10.1128/AAC.01027-1222908165
   PubMed Web of Science ®Google Scholar
• SutariaDS, MoyaB, GreenKB, et al. First penicillin-binding protein occupancy patterns of beta-lactams and beta-lactamase inhibitors in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.00282-18
   Web of Science ®Google Scholar
• WongD, NielsenTB, BonomoRA, PantapalangkoorP, LunaB, SpellbergB. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–447. doi:10.1128/CMR.00058-1627974412
   PubMed Web of Science ®Google Scholar
• ShapiroAB. Kinetics of sulbactam hydrolysis by beta-lactamases, and kinetics of beta-lactamase inhibition by sulbactam. Antimicrob Agents Chemother. 2017;61(12). doi:10.1128/AAC.01612-17
   Web of Science ®Google Scholar
• WangYC, KuoSC, YangYS, et al. Individual or combined effects of meropenem, imipenem, sulbactam, colistin, and tigecycline on biofilm-embedded Acinetobacter baumannii and biofilm architecture. Antimicrob Agents Chemother. 2016;60(8):4670–4676. doi:10.1128/AAC.00551-1627216052
   PubMed Web of Science ®Google Scholar